- Conditions
- Hypertrophic Cardiomyopathy (HCM)
- Interventions
- None - observational study
- Other
- Lead sponsor
- Christopher Kramer
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Evanston, Illinois • Boston, Massachusetts • Medford, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 48
- States / cities
- Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more
- Conditions
- Intermittent Claudication, Peripheral Artery Disease
- Interventions
- Placebo, 375 mg CK-2017357, 500 mg CK-2017357
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more
- Conditions
- Heart Failure
- Interventions
- Omecamtiv Mecarbil, Placebo, Standard of Care
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 8,256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 310
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 249 more
- Conditions
- Healthy Participants
- Interventions
- Aficamten, Aficamten-matching Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy Participants
- Interventions
- CK-3828136, Placebo for CK-3828136
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 26
- States / cities
- Fairhope, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- CK-2017357, Placebo tablets, Riluzole
- Drug · Other
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 38 more
- Conditions
- Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
- Interventions
- CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Heart Failure
- Interventions
- CK-1827452, Placebo
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- San Diego, California • Newark, Delaware
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Reldesemtiv, Placebo
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 489 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 30 more
- Conditions
- Symptomatic Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Aficamten (5 - 20 mg)
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more